SfN 2025 – A High-Content, Multiplex Platform for Investigating Lysosomal Dysfunction in Patient-Derived Fibroblasts: Applications in Neurodegeneration Drug Discovery

A Scalable Platform for Decoding Lysosomal Dysfunction in Neurodegenerative Disease

Mapping Cellular Defects to Drug Discovery

Lysosomal dysfunction is a key hallmark in neurodegenerative diseases like Alzheimer’s and Parkinson’s. But translating this biology into drug discovery demands robust, human-relevant models.

In this study, we present a high-content, multiplexed imaging platform using patient-derived fibroblasts to assess lysosomal integrity, autophagic flux, and rescue potential.

Our semi-automated system delivers scalable, quantitative phenotyping—ideal for screening compounds that modulate lysosomal function in disease-relevant contexts.

👉 Download the free poster to explore how this platform bridges human pathology and early-stage neuroscience drug discovery.